<DOC>
	<DOC>NCT00797797</DOC>
	<brief_summary>To evaluate the safety, tolerability, and efficacy of milnacipran when taken with another drug called pregabalin in people with fibromyalgia.</brief_summary>
	<brief_title>Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria tolerate at least 300 mg/day of pregabalin have an incomplete response to pregabalin treatment suicidal risk substance abuse pulmonary dysfunction renal impairment active cardiac disease liver disease narrow angle glaucoma autoimmune disease cancer inflammatory bowel disease unstable endocrine disease prostatic enlargement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>fibromyalgia</keyword>
	<keyword>milnacipran</keyword>
	<keyword>pregabalin</keyword>
	<keyword>treatment</keyword>
	<keyword>Forest Research Institute</keyword>
</DOC>